Dengue Vaccine Launches in India for First-Ever Phase-Three Clinical Trial
New Delhi: Dengue Vaccine in India has been launched the first-ever phase-three clinical trial by The Indian Council of Medical Research (ICMR) and Panacea Biotec Limited. This landmark trial will assess the effectiveness of DengiAll, an indigenous tetravalent Dengue vaccine developed by Panacea Biotec. The inaugural vaccination was administered at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak.
The significance of this trial lies in its potential to address a critical health gap in India. Currently, there are no licensed vaccines or antiviral treatments available for Dengue fever, a condition that has long posed a public health challenge in the region. The phase-three trial will be conducted across 19 sites spanning 18 states and Union Territories, involving more than 10,335 healthy adult participants.
This extensive trial aims to evaluate the vaccine’s efficacy in preventing dengue, which is caused by any of the four Dengue virus serotypes. Successful outcomes from this study could pave the way for the introduction of a licensed vaccine, significantly enhancing the country’s ability to combat dengue outbreaks.
The initiation of this trial marks a major step forward in India’s efforts to develop effective solutions against Dengue fever. It underscores the country’s commitment to advancing medical research and addressing pressing health issues through innovative, homegrown solutions.
FOLLOW FOR MORE.
